Satralizumab BLA Accepted by FDA for Treatment of NMOSD |
The FDA has accepted Genentech’s biologics license application (BLA) for satralizumab based on findings from 2 phase 3 trials that showed effectiveness in reducing risk of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD).
|
Read more
|
|